Literature DB >> 7652460

Detection of anti-bovine beta 2-glycoprotein I antibody in sera from patients with antiphospholipid syndrome.

M Nomura1, J Okada, H Kondo.   

Abstract

We studied and characterized anti-bovine beta 2-glycoprotein I antibodies (aB beta 2-GPI) in sera from patients with antiphospholipid syndrome (APS) by ELISA. Bovine beta 2-glycoprotein I (beta 2-GPI) was purified by heparin affinity and DEAE ion-exchange chromatography, and identified on immunoblots using a monoclonal antibody against human beta 2-GPI and by amino acid sequence analysis. aB beta 2-GPI levels in the sera from 36 APS patients were measured by ELISA using purified bovine beta 2-GPI as an antigen. The mean +/- standard deviation level of aB beta 2-GPI was 17.4 +/- 22.0 units in the 58% of APS patients who were positive. There was a significant correlation (P = 0.003) between aB beta 2-GPI and anticardiolipin antibody (aCL) levels. aB beta 2-GPI from the sera of patients with APS was inhibited by bovine beta 2-GPI itself. Purified IgG from the sera of patients with APS showed that bovine beta 2-GPI was capable of acting as a cofactor for aCL. Purified bovine beta 2-GPI was useful antigen for conventional ELISA. aB beta 2-GPI may contribute to the further development of aCL analysis and to the understanding of the pathogenesis of APS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7652460     DOI: 10.1007/bf00286762

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Apolipoprotein H (beta-2-glycoprotein I) polymorphism in Asians.

Authors:  N Saha; M I Kamboh; L J Kelly; R E Ferrell; J S Tay
Journal:  Hum Biol       Date:  1992-08       Impact factor: 0.553

2.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Suzuki; T Sumida; T Yasuda; T Koike
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

5.  beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles.

Authors:  H Wurm
Journal:  Int J Biochem       Date:  1984

6.  Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I.

Authors:  J Nimpf; E M Bevers; P H Bomans; U Till; H Wurm; G M Kostner; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1986-10-29

7.  Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

Authors:  R A Roubey; C W Pratt; J P Buyon; J B Winfield
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Antiphospholipid antibodies require beta 2-glycoprotein I (apolipoprotein H) as cofactor.

Authors:  J V Jones; H James; M H Tan; M Mansour
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

9.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

10.  Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.

Authors:  E Matsuura; Y Igarashi; T Yasuda; D A Triplett; T Koike
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  1 in total

1.  [A patient with mixed collagen disease, antiphospholipid syndrome and Sjögren syndrome].

Authors:  M Zuber; N Kranzhöfer; R Lindemuth; F Hartmann
Journal:  Med Klin (Munich)       Date:  1998-01-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.